Joshua Richter, MD - Charting a New Course in Relapsed/Refractory Multiple Myeloma: The Emergence of BCMA-Targeted Therapies

Please visit answersincme.com/CHW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology/oncology discusses multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs with current treatments for patients with relapsed/refractory multiple myeloma (RRMM); Review the role of B-cell maturation antigen (BCMA) as a therapeutic target in multiple myeloma; and Outline clinical considerations for incorporating emerging BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM, based on available evidence.

There are no comments yet.

Please log in to write the first comment.